Abstract
A new guideline from the US has neatly summarized the evidence regarding the use of 5α-reductase inhibitors for prostate disease, but falls short of providing definitive management recommendations. It will, however, be a valuable aid to both patients and physicians in the clinical decision-making process.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
